Effect of deoxyribonuclease I treatment for dementia in end-stage Alzheimer's disease: a case report.
Effect of deoxyribonuclease I treatment for dementia in end-stage Alzheimer's disease: a case report.
复制标题
DOI：
10.1186/s13256-016-0931-6
复制
发表时间：
2016-05-28
影响因子：
1
通讯作者：
Tetz G
中科院分区：
文献类型：
--
作者：
Tetz V;Tetz G
阿尔茨海默病是痴呆症最常见的原因，其特征是脑组织进行性丧失，导致β-淀粉样蛋白积累和认知功能严重下降。人们对阿尔茨海默病的病因知之甚少，可用的治疗方法疗效有限，特别是对于症状更严重的患者。我们报道了一名 77 岁的白人男性，患有严重痴呆和继发于阿尔茨海默氏病的行为障碍，接受美金刚治疗，他开始使用脱氧核糖核酸酶 I 进行辅助治疗。在开始脱氧核糖核酸酶 I 治疗之前，我们的患者似乎处于昏迷状态，简易精神状态检查得分为 3，功能评估分期测试得分为 7。在获得家庭成员的知情同意后，我们开始给予每天 120 毫克脱氧核糖核酸酶 I (1500 KU/mg)，用于治疗严重认知障碍。在开始脱氧核糖核酸酶 I 治疗后 2 天，我们的患者开始表现出认知功能快速、显着的改善。持续治疗2个月后，简易精神状态检查和功能评估分期测试得分分别为18分和4分。
Alzheimer's disease is the most common cause of dementia and is characterized by a progressive loss of brain tissue leading to amyloid-β accumulation and severe decline in cognitive function. The cause of Alzheimer’s disease is poorly understood, and available treatments are limited in their efficacy, particularly for patients with more severe symptoms. We report the case of a 77-year-old Caucasian man with severe dementia and behavioral disturbance secondary to Alzheimer’s disease treated with memantine who began adjunct treatment with deoxyribonuclease I. Prior to initiation of deoxyribonuclease I treatment, our patient appeared to be in a stuporous state, with a Mini-Mental State Examination score of 3 and a Functional Assessment Staging Test score of 7. After obtaining informed consent from family members, we started administration of 120 mg of deoxyribonuclease I per day (1500 KU/mg) for treatment of severe cognitive impairment. Our patient began to demonstrate rapid, considerable improvement in cognitive function 2 days following initiation of deoxyribonuclease I treatment. After 2 months of continued treatment, Mini-Mental State Examination and Functional Assessment Staging Test scores were 18 and 4, respectively.